Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms

The Special Operations Care-Fund (SOC-F) will sponsor the application of four treatments - hormone replacement, magnetic resonance brain stimulation, ibogaine, and 5-Meo-DMT - to Special Operations Forces veterans with a history of combat deployments, traumatic brain injury, and problems with mental health and cognitive functioning. An observational study will be conducted in parallel by the Johns Hopkins Center for Psychedelic and Consciousness Research to determine the effectiveness and safety of each treatment, primarily through measuring post-treatment changes in PTSD symptoms and cognitive functioning.

开始日期2025-09-01

申办/合作机构

The Johns Hopkins University

NCT06812221

/ Completed临床1/2期

A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Trial of Multiple Sublingual 5-MeO-DMT Microdoses for Reducing Anxiety and/or Depression in Patients With Mild Cognitive Impairment.

This Phase I/II clinical trial aims to test the effectiveness of a new sublingual formulation of 5-MeO-DMT in reducing symptoms of anxiety, depression, and cognitive decline in individuals with mild to moderate Alzheimer's disease. The study will include participants who have a Clinical Dementia Rating (CDR) score between 0.5 and 1, indicating mild to moderate cognitive impairment, and who meet specific educational and cognitive criteria. Participants must have an ACE-III score of ≤86 for individuals with a high level of education (≥12 years) or <62 for those with a low educational level (≤12 years). Additionally, participants must show moderate to high levels of anxiety, as indicated by the State-Trait Anxiety Inventory (STAI), with STAI-S (State) scores ≥20 for men and ≥23 for women, and STAI-T (Trait) scores ≥20 for men and ≥26 for women. Participants also need to exhibit moderate to severe depressive symptoms, as indicated by a Beck Depression Inventory (BDI) score of ≥21.
To ensure that participants are cognitively functional but showing signs of impairment, they are assessed with the CDR and ADLQ scales to confirm they can maintain independence in daily activities. All participants must have scores above the threshold on cognitive screening tests like the ACE III and IFS, ensuring no significant cognitive impairment at the baseline.
The study will measure the effects of 5-MeO-DMT through a range of cognitive and psychiatric assessments:
Cognitive Assessments: These include the Rey Auditory Verbal Learning Test (RAVLT) for episodic memory, the Trail Making Test (TMT) for attention and cognitive flexibility, the Semantic and Phonological Fluency Test (SFT-FAS) for verbal fluency, the Paced Auditory Serial Addition Test (PASAT) for processing speed, and the Digit Span Subtests (DSS) for attention and working memory. These tests will provide valuable insights into how 5-MeO-DMT affects cognitive functions.
Psychiatric Assessments: These will assess symptoms of suicidal ideation (SSI), mood (BDI II), anxiety (STAI), and mindfulness (FFMQ), as well as self-reported cognitive complaints (CQC). These evaluations will help determine the psychological and emotional impact of 5-MeO-DMT on participants.
In addition, the study will include biochemical assessments such as microalbuminuria, blood glucose levels, liver and kidney function, cholesterol, and several biomarkers of inflammation. Cardiovascular evaluations will also be conducted during the trial, ensuring comprehensive monitoring of potential side effects.
This structured approach will help researchers assess the cognitive and psychological effects of 5-MeO-DMT in individuals with mild to moderate Alzheimer's disease. By focusing on participants with elevated anxiety, depression, and early cognitive decline, this trial aims to provide insights into the therapeutic potential of 5-MeO-DMT for neurodegenerative conditions.

开始日期2024-12-15

申办/合作机构

Biomind Labs, Inc.

[+1]

NCT06511947

/ Recruiting临床1期

An Open-label Phase 1 Trial to Determine the Pharmacokinetics, Pharmacodynamics, and Safety of GH001 Administered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration and a single-day individualized dosing regimen (IDR). As secondary objectives, the mebufotenin PK/ pharmacodynamic (PD) relationship, the PD profile of GH001 as evaluated by its psychoactive effects (PsE), the impact on cognitive performance, and the TCmax/2 and TCmax/10 (time taken for Cmax to decrease by 50 and 90%, respectively) are also assessed.

开始日期2024-08-01

申办/合作机构

GH Research Plc

100 项与蟾蜍素相关的临床结果

登录后查看更多信息

100 项与蟾蜍素相关的转化医学

登录后查看更多信息

100 项与蟾蜍素相关的专利（医药）

登录后查看更多信息

832

项与蟾蜍素相关的文献（医药）

2025-10-01·NEUROPSYCHOPHARMACOLOGY

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

Article

作者: Ortiz, Javier E ; Bruno, Diana ; Kassuha, Diego E ; Vita, Luciana ; Garcés, M Agustina ; Orosco, Lorena ; Bruno, Martin A ; Zanino, Mariana ; Bistue Millón, Maria Beatriz ; Diez, Pablo ; Feresin, Gabriela E ; Díaz-Dellavalle, Paola ; Albarracín, Sergio G ; Noguera, Laura

This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of 5-MeO-DMT, administered at sub-psychedelic doses to adults with moderate to high levels of anxiety and/or depression, without formal psychiatric diagnosis or ongoing treatment. Using a double-blind, placebo-controlled design, participants received a single weekly sublingual dose of 5-MeO-DMT (6 mg, 9 mg, or 12 mg) or placebo over four weeks. The compound was well tolerated across all groups, with no significant adverse events or signs of organ toxicity; mild side effects such as nausea and headache were transient and self-resolving. Pharmacokinetic analyses showed rapid absorption, with peak plasma concentrations occurring within a median of 20 min and no evidence of drug accumulation. Neurophysiological assessments revealed dose-dependent modulation of brain activity without eliciting full psychedelic effects, supporting the feasibility of repeated sub-psychedelic dosing. Participants remained cognitively and behaviorally stable, maintaining their usual daily activities and social interactions. This study marks a pivotal advancement in the clinical exploration of psychedelic compounds, highlighting the potential of 5-MeO-DMT as a safe, fast-acting compound with favorable tolerability and emerging as a promising candidate for future therapeutic applications. These findings provide critical groundwork for future trials targeting psychiatric populations, positioning 5-MeO-DMT as a novel, fast-acting therapeutic strategy with broad clinical relevance. TRIAL REGISTRATION: ClinicalTrials.gov: NCT06816667.

2025-08-25·Sheng wu gong cheng xue bao = Chinese journal of biotechnology

[Establishment and application of a high-throughput screening method for drugs targeting the 5-hydroxytryptamine 2A receptor based on cellular calcium flux signals].

Article

作者: Chen, Yuanqing ; Zhang, Ruihua ; Li, Liqin ; Shi, Jingjing ; Wang, Miao ; Zhang, Bingqian ; Zhang, Yi

The 5-hydroxytryptamine 2A receptor (5-HT_2AR) is one of the key targets in the development of novel antidepressants. To develop new antidepressants targeting the 5-HT_2A receptor, this study established a high-throughput screening method for drugs targeting the 5-HT_2A receptor based on the principle of detecting calcium flux signals. The immunofluorescence assay and western blotting were employed to evaluate receptor expression levels in the 5-HT_2AR-CHO cell line. The reaction system parameters, including cell seeding density, DMSO concentration, and dye incubation time, were optimized with Z'-factor and signal window values as evaluation indicators. The specificity, precision, stability, and applicability of the method were assessed. Results indicated that the 5-HT_2AR-CHO cell line stably expressed high levels of the 5-HT_2A receptor. The optimized screening method involved a reaction system with 10 000 cells/well, 0.2% DMSO, and 2 h incubation with Calcium 6 dye. The method demonstrated excellent specificity, with inter-batch precision below 10% for the detection of 5-hydroxytryptamine (5-HT) at low, medium, and high concentrations. Testing four compounds that target the 5-HT_2A receptor- agonists 2,5-dimethoxy-4-iodoamphetamine (DOI), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and lysergic acid diethylamide (LSD), along with the antagonist MDL100907-yielded Z'-factors (at EC₈₀) greater than 0.85 and signal window values over 0.91. The EC₅₀ values of these compounds were in the nanomolar range, and their potency rank order aligned with previously reported data, confirming the reliability of the established method. When being applied to the detection of 38 known active compounds, the method efficiently identified 5-HT_2A receptor agonists and antagonists while showing no response to non-target compounds. In conclusion, this study successfully constructs a high-throughput screening approach for 5-HT_2A receptor-targeting drugs based on calcium flux signals. The method possesses strong specificity, high sensitivity, and robust stability, being suitable for screening antidepressants targeting the 5-HT_2A receptor.

2025-08-01·BIOLOGICAL PSYCHIATRY

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action

Review

作者: Kobayashi, Nene F ; Reif, Andreas ; Bayas, Maximilian ; Möser, Chiara ; Repple, Jonathan

After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression due to the reduced risk of mania induction, research on RAADs, such as (es)ketamine, remains scarce despite their demonstrated safety and effectiveness. In this review, we give an overview of current developments in RAADs in the context of bipolar disorder. Both published studies as well as phase II, III, and IV studies on bipolar depression (based on ClinicalTrials.gov) are reviewed in this work. The following RAAD substance classes have been or are currently being investigated as possible treatments for bipolar depression: NMDA antagonists and indirect AMPA agonists (ketamine, esketamine, riluzole, felbamate), GABA_A (gamma-aminobutyric acid A) activators or positive allosteric modulators (zuranolone, pregnenolone, PEA), psychedelics (psilocybin, 5-MeO-DMT), muscarine receptor antagonists (scopolamine), and kappa opioid receptor antagonists (navacaprant). Other than the well-established efficacy and safety of (es)ketamine in treating bipolar depression, there has been little research effort in the treatment of bipolar depression. Recent research into RAADs demonstrates the growing field of novel mechanisms of action in the pharmacological treatment of bipolar depression. However, there is an urgent need for well-controlled clinical studies on RAADs in bipolar depression to expand treatment options and improve outcomes for millions of affected individuals worldwide.

147

项与蟾蜍素相关的新闻（医药）

2026-01-02

·investor.ghres.com

GH Research to Announce IND Status for GH001

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST. About GH Research PLC GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD. About GH001 Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), we believe that GH001 has the potential to change the way TRD is treated today. Investor Relations: Julie Ryan GH Research PLC investors@ghres.com

临床2期临床3期临床申请

2025-12-31

·GlobeNewswire-Health Care

AtaiBeckley Completes Redomiciliation to the United States

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company’s extraordinary general meeting of shareholders on November 4, 2025. The redomiciliation was completed following the close of trading on the Nasdaq Global Market on December 30, 2025. At completion, all issued and outstanding ordinary shares of Atai Beckley N.V. were exchanged on a one-for-one basis for newly issued shares of common stock of the Delaware company, AtaiBeckley Inc. The former shareholders of Atai Beckley N.V. are now the stockholders of the Delaware company. AtaiBeckley Inc’s common stock will continue to trade on NASDAQ under the trading symbol “ATAI”. The Company expects the redomiciliation to save costs, create alignment with its U.S. listing and shareholder base, simplify its corporate structure and streamline reporting requirements, in addition to reducing the associated administrative burden for the Company and investors. For more information on the redomiciliation of the Company, please refer to the Company’s filings with the Securities and Exchange Commission, which are available on its Investor Relations website. About AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. It was formed through the strategic combination of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable, and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: the potential benefits of the redomiciliation; our business strategy and plans; the potential, success and timing of development and progress of trials and related milestones of our product candidates; and the plans and objectives of management for future operations, research and development and capital expenditures. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in AtaiBeckley’s other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact InformationInvestor Contact:IR@ataibeckley.com Media Contact:PR@ataibeckley.com

临床2期上市批准

2025-12-25

·药时代

安慰剂“杀疯”了？抑郁症研发药企众生相

出海机会来了！欧美药企寻找已上市、临床3期抗实体瘤创新药产品，希望有差异化、专利期长，优先考虑买断海外权益！请感兴趣的公司立即联系：药时代BD团队 BD@drugtimes.cn 正文共：2415字预计阅读时间：7分钟当被问及在CNS新药研发领域，最大的瓶颈是什么？答案往往指向那几个熟悉的名字：难以逾越的血脑屏障、复杂未知的疾病机制、依赖主观表达的临床评估，以及难以捉摸的安慰剂效应。行业数据显示，CNS药物在II/III期临床试验中的失败率惊人地高达约85%。以重度抑郁症（MDD）为例，这一影响全球数亿人的疾病，在2009至2025年间，仅迎来了15款获FDA批准的新药。在许多试验中，看似不起眼的安慰剂（“糖丸”或“淀粉片”）却屡屡表现出媲美新药的疗效，甚至成为试验未能达到统计学显著性的关键原因。这迫使整个领域直面一个更深层的拷问：当安慰剂效应如此强大且普遍，我们究竟是在测试药物的真实疗效，还是在测量人类大脑对“期望”自身的复杂反应？ BHV-7000在CNS中，再度折戟 2025年岁末，Biohaven其新型钾通道调节剂BHV-7000在治疗重度抑郁症的II期研究中，未达到其主要终点。该研究评估了6周内蒙哥马利-阿斯伯格抑郁量表（MADRS）评分的变化，结果显示BHV-7000与安慰剂相比无统计学显著差异。 BHV-7000的作用机制颇具新意，它旨在选择性激活大脑中的Kv7.2/Kv7.3钾离子通道，该通道在神经信号传导和调控神经元过度兴奋状态中发挥关键作用，适用于癫痫和情绪障碍等疾病的治疗。目前，该靶点尚无药物获批。该评估所采用的MADRS量表涵盖情绪低落、精神紧张、睡眠、食欲等10个项目，由经过培训的专业人员通过半结构化访谈进行评分，其结果结合了行为观察与患者陈述，可靠性较高。分数越高表示抑郁程度越严重。左右滑动查看更多临床数据尽管BHV-7000在整体人群中疗效未显著优于安慰剂，但在那些基线病情极为严重的患者亚组中，观察到了一致的积极趋势。在这部分重症患者中，BHV-7000不仅在其主要终点上呈现更大幅度的降低，在两项关键次要终点：临床总体印象-严重度量表（CGI-S：反映医生对患者整体病情的评估）和斯奈斯-汉密尔顿快感量表（SHAPS：衡量“快乐感受能力”的快感缺失量表）上，也呈现出数值上的显著改善。在安全性方面，BHV-7000表现出良好的耐受性。大多数不良事件为轻中度且可自行缓解，中枢神经系统相关不良反应的发生率较低，这与其不作用于GABA系统的作用机制特点相符。然而，商业研发是现实的。基于整体研究未达主要终点的结果，以及公司整体的战略资源分配，Biohaven决定将研发重点转向免疫学、肥胖症及癫痫等优先领域，不计划开展额外的精神病学临床试验。这一决定并不意外。今年3月，BHV-7000在用于治疗急性双相障碍躁狂发作的II/III期研究中也未能达到主要终点。如今，其科学价值能否得到证实，将全部希望押注在预计于2026年公布的、针对局灶性癫痫的首个关键临床数据。 2025：抑郁症新药研发的“寒冬” BHV-7000的遭遇并非个例。2025年，多款机制迥异的抗抑郁药物在临床试验中接连遇阻，为这一复杂疾病的新药探索之路再添寒意。 KOR拮抗剂路径遇冷 κ-阿片受体（KOR）拮抗剂曾被寄予厚望。然而，今年1月，Neumora宣布其KOR拮抗剂Navacaprant针对重度抑郁症的首个III期试验中，未能显示出相较于安慰剂在统计学上的显著改善。受此信息影响，Neumora股价暴跌超过80%，创下这家公司上市以来的最大单日跌幅！同时，这也是2025年开年首个跌幅如此之高的BioTech。随后，公司调整了另外两项III期研究的设计，Navacaprant得以“续命”。而强生的KOR拮抗剂则痛失了 “复活赛”的机会。今年3月，强生发表声明称因"在目标患者群体中疗效不足"，已决定终止Ventura III期临床开发项目，该项目旨在评估Aticaprant作为重度抑郁症辅助治疗的疗效。不过，强生表示会继续巩固在其神经科学领域的领导地位。 H3受体阻滞剂与BDNF靶向药：双线受挫今年6月，Alto Neuroscience报告其口服组胺H3受体阻滞剂ALTO-203在抑郁症试验中未能显著改善患者情绪，且高剂量组的表现并未优于安慰剂。这一结果迫使公司深入研究探索性终点，并寻找脑电图生物标志物的疗效信号，例如θ/β（theta/beta）。祸不单行，Alto公司另一款口服药物ALTO-100，在IIb期试验中也未能显著击败安慰剂。这或许归因于患者治疗依从性较低，超过30%分配至药物组的患者未按规定服药。值得一提的是，该款药物由Alto利用其生物标志物平台所开发，其靶点为脑源性神经营养因子（BDNF），可恢复患者的神经可塑性，使大脑能够灵活适应新信息。 mTORC通路尝试未果 Supernus Pharmaceuticals试图通过口服激活mTORC蛋白来攻克难治性抑郁症（TRD），但其候选药SPN-820在IIb期试验中未能显示出与安慰剂具有统计学显著差异的疗效，主要终点及关键次要终点均未达成。该公司后续表示，计划在重度抑郁症中启动新的IIb期试验，但未提及在难治性抑郁症中的进一步试验。 NMDA受体调控剂意外失败更令业界意外的是靶向NMDA受体通路药物的接连受挫折。7月，Relmada Therapeutics宣布停止其NMDA受体拮抗剂艾司美沙酮（esmethadone）的开发，因其III期未能达到「抑郁症症状评分改善」的主要终点。药物组与安慰剂组之间的差异过小，并未达到统计学显著水平。 11月，Neurocrine Biosciences的NMDA NR2B受体负向变构调节剂NBI-1070770也在II期研究中错过主要终点，未能显著改善抑郁严重程度。对此，有分析师感到不解，因为相似机制药物，例如强生的艾司氯胺酮鼻喷雾剂Spravato和Axsome的口服NMDA受体拮抗剂Auvelity已获批上市。鉴于已有先例，此类药物原本被视为“风险相对较低”的路径。致幻药物异军突起，却面临商业化难题当然，抑郁症药物开发也并非“无药生还”，今年多款致幻类药物在寒潮凛冽中取得了突破性进展，为行业注入了新的希望。 6月，Compass Pathways公布裸盖菇素疗法COMP360在难治性抑郁症（TRD）中的首批III期临床数据显示：治疗6周后，患者抑郁评分（MADRS）较安慰剂降低3.6分，达到主要终点。Compass称这一结果“具有临床意义”和“高度统计意义”，为其后续上市申请奠定了基础。 10月，Atai Life宣布其色胺类致幻剂5-HT1AR激动剂BPL-003（甲氧色胺苯甲酸盐鼻喷制剂）难治性抑郁症（TRD )获FDA授予突破性疗法认证（BTD）。其II期数据显示，29天后，接受12毫克BPL-003治疗的患者在MADRS上的分数比基线下降了11.1分，8毫克的低剂量水平也优于对照治疗。疗效数据被Jefferies分析师评价为“强健”，并预测其销售峰值可能达到10亿美元。然而，常言道“药有三分毒”。而许多迷幻物质本身在社会认知中便与“毒品”紧密关联，使得其商业化之路布满荆棘。即使致幻药物成功获批，对长期安全性、潜在滥用风险的持续担忧，以及高昂的治疗成本，都将构成医保支付和广泛可及性的障碍。例如，强生的艾司氯胺酮鼻喷雾剂 Spravato（艾氯胺酮为“K粉”的一类 “变种”）就三次被英国国家医疗服务体系（NHS）拒之门外。这意味着，致幻疗法从“科学上的成功”走向“患者可及的治疗”，仍需穿越一片复杂的认知、监管与支付险滩。结语抑郁症病因错综复杂，由遗传、环境等多重因素交织，至今仍无单一理论能完全破解其生物学机制。这一根本性的科学认知鸿沟，使得新药研发充满挑战。然而，巨大的未满足需求仍驱动着市场不断前行。据Modor Intelligence报告，全球抗抑郁药物市场在2024-2029年间预计将以3.5%的复合年增长率扩张，其中亚太地区将成为增长最快的引擎。这些跌宕起伏的研发故事，共同指向一个核心：我们对于大脑情绪回路的理解依然浅层，寻找真正起效的疗法，犹如在暴风雪中描绘地图。然而，道阻且长，每一步探索，都有意义。封面图：剧照《丈夫得了抑郁症》参考资料： 1.https://ir.biohaven.com/news-releases/news-release-details/biohaven-provides-update-phase-2-proof-concept-study-bhv-7000 2.https://www.biospace.com/drug-development/5-depression-trials-that-failed-in-2025 3.被安慰剂“做了局”？又一款CNS药物倒下了 4.安慰剂“杀疯”了？CNS研发药企众生相 5.87亿美元豪赌折戟后，艾伯维再投12亿美元！6.其他公开资料版权声明/免责声明本文为原创文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！

100 项与蟾蜍素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	蟾蜍素	-	DB14010

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
轻度认知障碍	临床2期	阿根廷	Biomind Labs, Inc.	2024-12-15
焦虑症	临床2期	阿根廷	Biomind Labs, Inc.	2024-10-21
抑郁症	临床2期	阿根廷	Biomind Labs, Inc.	2024-10-21
酒精使用障碍	临床2期	英国	Beckley Psytech Ltd.	2023-05-30
躁郁症2型	临床2期	德国	GH Research Plc	2023-04-06
躁郁症2型	临床2期	荷兰	GH Research Plc	2023-04-06
躁郁症2型	临床2期	英国	GH Research Plc	2023-04-06
重度抑郁症	临床2期	德国	GH Research Plc	2023-04-06
重度抑郁症	临床2期	荷兰	GH Research Plc	2023-04-06
重度抑郁症	临床2期	英国	GH Research Plc	2023-04-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05870540 (GlobeNewswire) 人工标引	临床2期	难治性抑郁症	-	BPL-003 12 mg（first 0.3 mg）	願壓築鏇壓製齋膚淵齋(選鹽積齋選簾齋齋獵構) = 鬱繭構築淵遞齋鏇鹹齋願構膚餘衊艱膚鬱壓獵 (製獵簾獵膚簾艱顧選襯 )	积极	2025-11-10
NCT05870540 (GlobeNewswire) 人工标引	临床2期	难治性抑郁症	-	BPL-003 12 mg（first 8mg）	願壓築鏇壓製齋膚淵齋(選鹽積齋選簾齋齋獵構) = 築鏇淵糧淵窪艱蓋糧網願構膚餘衊艱膚鬱壓獵 (製獵簾獵膚簾艱顧選襯 ) 更多	积极	2025-11-10
NCT05660642 (Company_Website) 人工标引	临床2期	难治性抑郁症	12	BPL-003	願構艱範鹽鬱築鹹齋構(淵襯憲積網窪夢鑰願夢) = 憲鑰憲窪憲壓願遞構鹹淵獵鹽齋網築築簾廠餘 (壓鬱淵觸簾鹹壓鹹衊網 ) 更多	积极	2025-09-23
NCT05753956 (NEWS)	临床1期	抑郁症	-	GH002	製鬱遞齋範憲膚夢蓋鬱(顧鏇鏇簾齋淵鹹醖簾鹹) = None 築選獵遞獵夢顧繭獵鬱 (餘鏇遞構鑰廠艱膚齋遞 ) 更多	积极	2025-08-07
NCT05660642 (GlobeNewswire) 人工标引	临床2期	难治性抑郁症	12	BPL-003 + SSRIs	簾膚繭構廠衊簾觸網齋(膚鏇廠淵壓壓範鹹憲鑰) = 繭製鏇壓夢觸壓襯遞壓鹽艱鹹選膚糧鹹蓋壓願 (獵繭齋廠顧願襯蓋獵鹽 ) 更多	积极	2025-05-20
NCT05800860 (GH001-TRD-201, Company_Website 1 \| Company_Website 2 \| Company_Website 3 \| Company_Website 4) 人工标引	临床2期	难治性抑郁症	81	GH001	襯蓋艱鏇製獵餘獵壓窪(蓋壓壓構淵獵蓋蓋鹹網) = 齋願齋艱製選壓淵鑰積憲遞積衊顧繭鏇構齋繭 (窪範選鬱憲糧鬱願淵鬱 ) 达到更多	积极	2025-02-03
	临床2期	难治性抑郁症	81	Placebo	襯蓋艱鏇製獵餘獵壓窪(蓋壓壓構淵獵蓋蓋鹹網) = 構齋願構鏇齋襯醖蓋襯憲遞積衊顧繭鏇構齋繭 (窪範選鬱憲糧鬱願淵鬱 ) 达到更多	积极	2025-02-03
NCT05804708 (Company_Website) 人工标引	临床2期	产后抑郁症	10	GH001	積鏇夢鬱齋淵範夢範積(襯簾獵鑰蓋鏇遞鹹蓋顧) = 獵繭鹽製衊構餘鬱醖繭蓋網醖齋選膚鹽鑰鹽醖 (夢衊餘壓顧窪鏇網衊構 ) 达到更多	积极	2025-01-10
NCT05839509 (Company_Website) 人工标引	临床2期	躁郁症2型	6	GH001	鏇膚積簾遞顧觸範鏇艱(顧餘願範壓鑰鏇襯鏇蓋) = 遞遞夢夢網鹹艱鏇壓淵夢窪餘鹹鏇鏇鹽願鹹憲 (繭製淵積憲糧構鑰鬱願 ) 达到更多	积极	2025-01-10
NCT05660642 (Corporate Publications) 人工标引	临床2期	难治性抑郁症	11	BPL-003 10mg	淵襯醖製獵齋壓襯築餘(糧繭膚鏇觸獵壓構窪衊) = 夢獵窪選網襯鑰膚鏇鹹範鹽醖壓壓窪積夢鹹獵 (夢網遞顧襯廠鏇憲淵觸 ) 更多	积极	2024-03-27
BusinessWire 人工标引	临床2期	阿尔茨海默症 \| 抑郁症 \| 焦虑症	40	BMND08 12mg	夢憲願窪夢醖積壓網鹽(獵餘鏇鬱膚鹹獵網鹽鹽) = 獵齋鹹顧製淵獵積艱繭積襯鬱糧夢網醖艱築鬱 (憲衊襯簾醖憲鬱顧醖範 ) 更多	积极	2024-02-29
BusinessWire 人工标引	临床2期	阿尔茨海默症 \| 抑郁症 \| 焦虑症	40	BMND08 9mg	夢憲願窪夢醖積壓網鹽(獵餘鏇鬱膚鹹獵網鹽鹽) = 築壓窪選構窪餘鏇願鬱積襯鬱糧夢網醖艱築鬱 (憲衊襯簾醖憲鬱顧醖範 )	积极	2024-02-29